Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAU-284 in pediatric perennial allergic rhinitis
NCT01425632Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Aug 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bepotastine in perennial allergic rhinitis (PAR) (3 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Change From Baseline in Total Score for the Three Major Nasal Symptoms (Sneezing, Rhinorrhea, and Nasal Congestion) at 2 weeks. Started Aug 2011; status: completed.
02
Drugs
bepotastine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01425632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01425632.